All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
Impella Supported OPCABG
Impella-Supported Off-pump Coronary Artery Bypass Grafting in High-Risk Revascularizations: A Single Center Prospective Observational Study
EXPANSE PTCA
A study to Exhibit Percutaneous coronary artery dilation with non-slip element balloon
STRIKE-PE
A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism
ACURATE IDE
Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
CLASP II TR Pivotal Trial (PASCAL)
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP II TR)
This trial is designed as a multicenter, randomized, controlled pivotal trial to compare the safety and effectiveness of the PASCAL System and optimal medical therapy to optimal medical therapy alone for patients with tricuspid regurgitation.
Tendyne SUMMIT
This is a clinical trial to evaluate the safety and effectiveness of using the Tendyne Mitral Valve System for the treatment of symptomatic mitral regurgitation compared to the MitraClip System.
CATALYST
Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants
The CATALYST Trial will compare treatment with Abbott’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treatment with non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation at high-risk for stroke.
PATH-HHT
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
The purpose of this study is to determine efficacy of pomalidomide compared to placebo for the reduction in severity of epistaxis after 24 weeks of treatment.
ECMOCARD
ExtraCorporeal Membrane Oxygenation for 2019 Novel Coronavirus Acute Respiratory Disease
The purpose of this study is to describe clinical features; severity of pulmonary dysfunction; incidence of ICU admission and use of mechanical ventilation and ECMO; ECMO technical characteristics; duration of ECMO; complications; and survival of patients with COVID-19.
Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)
This study is being done to determine the impact of the TIPS procedure on cardiac (heart) function by collecting data (heart pressures) during the IPS procedure. Immediately after TIPS and at standard follow-up time points, labs and transthoracic echocardiograms (TTE or echo) will also be collected.
TAVR Unload
The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate aortic stenosis (AS) compared with optimized heart failure therapy (OHFT).
The C-TRACT Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy
Determine if the use of imaging-guided endovascular therapy (EVT) is an effective strategy with which to reduce Post-Thrombotic (PTS) disease severity and improve quality of life (QOL) in patients with established disabling iliac-obstructive post-thrombotic syndrome (DIO-PTS).
Effect of Probiotic Supplementation on Endothelial Function
To determine whether daily supplementation with the probiotic Lactobacillus plantarum 299v improves the function of blood vessels in patients with coronary artery disease.
MINT
Myocardial Ischemia and Transfusion
The purpose of this study is to assess among patients with an acute myocardial infarction and a hemoglobin concentration less than 10 g/dL, if a liberal transfusion strategy with a threshold of 10 g/dL reduces the rate of the composite outcome of all-cause mortality or recurrent nonfatal acute myocardial infarction through 30 days following randomization compared to a restrictive transfusion strategy with a threshold of 7 to 8 g/dL.